CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 10, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company
engaged in the discovery and development of DNA- and RNA-based drug
candidates targeted to Toll-like Receptors (TLR), today announced that
it will present a corporate overview at the Cowen and Company 29th
Annual Health Care Conference on Wednesday, March 18, at 10:15 a.m. (ET)
at the Boston Marriott Copley Place in Boston, MA.
The presentation will be available via live audio webcast on the
Company’s website at www.iderapharma.com.
Archived replays will also be located on the Company’s site following
the event.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals develops drug candidates to treat infectious
diseases, autoimmune diseases, cancer, and respiratory diseases, and for
use as vaccine adjuvants. Our proprietary drug candidates are designed
to modulate specific Toll-like Receptors, which are a family of immune
system receptors that direct immune system responses. Our pioneering DNA
and RNA chemistry expertise enables us to create drug candidates for
internal development and generates opportunities for multiple
collaborative alliances. For more information, visit www.iderapharma.com.
Idera Forward Looking Statements
This press release contains forward-looking statements concerning Idera
Pharmaceuticals, Inc. that involve a number of risks and uncertainties.
For this purpose, any statements contained herein that are not
statements of historical fact may be deemed to be forward-looking
statements. Without limiting the foregoing, the words "believes,"
"anticipates," "plans," "expects," "estimates," "intends," "should,"
"could," "will," "may," and similar expressions are intended to identify
forward-looking statements. There are a number of important factors that
could cause the Company’s actual results to differ materially from those
indicated by such forward-looking statements, including whether products
based on the Company’s technology will advance into or through the
clinical trial process on a timely basis or at all and receive approval
from the United States Food and Drug Administration or equivalent
foreign regulatory agencies; whether, if the Company’s products receive
approval, they will be successfully distributed and marketed; whether
the Company’s cash resources will be sufficient to fund the its
operations; and such other important factors as are set forth under the
caption "Risk Factors" in the Company’s Quarterly Report on Form 10-Q
filed on November 6, 2008, which important factors are incorporated
herein by reference. The Company disclaims any intention or obligation
to update any forward-looking statements.
Source: Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc.
Kelly Luethje, 617-679-5519
kluethje@iderapharma.com
or
MacDougall
Biomedical Communications
Chris Erdman, 781-235-3060
cerdman@macbiocom.com